{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:41:03Z","timestamp":1792536063230,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","award":["2024-27"],"award-info":[{"award-number":["2024-27"]}],"id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmogo.2026.100382","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:00:19Z","timestamp":1784538019000},"page":"100382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Clinician and patient attitudes toward locoregional treatment of oligometastatic oesophago-gastric cancers: a mixed-methods study"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9525-127X","authenticated-orcid":false,"given":"A.S.","family":"Lakha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gordon-Weeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4040-5681","authenticated-orcid":false,"given":"S.R.","family":"Markar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10110","key":"10.1016\/j.esmogo.2026.100382_bib3","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0140-6736(17)31462-9","article-title":"Oesophageal cancer","volume":"390","author":"Lagergren","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100382_bib4","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1007\/s12029-022-00900-5","article-title":"Oligometastatic colorectal cancer: a review of definitions and patient selection for local therapies","volume":"54","author":"Miller","year":"2023","journal-title":"J Gastrointest Cancer"},{"issue":"24","key":"10.1016\/j.esmogo.2026.100382_bib5","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.3390\/cancers15245873","article-title":"The diagnosis and treatment approach for oligo-recurrent and oligo-progressive renal cell carcinoma","volume":"15","author":"Bekku","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100382_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.athoracsur.2024.11.010","article-title":"The Society of Thoracic Surgeons (STS) clinical practice guideline on surgical management of oligometastatic non-small cell lung cancer","volume":"119","author":"Antonoff","year":"2025","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100382_bib7","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1245\/s10434-024-14997-4","article-title":"Prediction of morbidity and mortality after esophagectomy: a systematic review","volume":"31","author":"van Nieuw Amerongen","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100382_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0016-5085(99)70175-7","article-title":"Micrometastases in esophagogastric cancer: high detection rate in resected rib segments","volume":"116","author":"O\u2019Sullivan","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.esmogo.2026.100382_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.21037\/dmr-21-94","article-title":"Gastric adenocarcinoma peritoneal carcinomatosis: a narrative review","volume":"5","author":"Green","year":"2022","journal-title":"Dig Med Res"},{"key":"10.1016\/j.esmogo.2026.100382_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2023.02.015","article-title":"Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a Delphi consensus study in Europe","volume":"185","author":"Kroese","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmogo.2026.100382_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114062","article-title":"European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)","volume":"204","author":"Kroese","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100382_bib12","doi-asserted-by":"crossref","first-page":"9651","DOI":"10.1038\/s41467-025-65148-6","article-title":"Modeling and addressing on-target\/off-tumor toxicity of claudin 18.2 targeted immunotherapies","volume":"16","author":"Carstens","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100382_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5005\/jp-journals-10018-1321","article-title":"A systematic review and meta-analysis of PD-1 and PD-L1 inhibitors monotherapy in metastatic gastric and gastroesophageal junction adenocarcinoma","volume":"10","author":"Voutsadakis","year":"2020","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"10.1016\/j.esmogo.2026.100382_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102789","article-title":"HER-2 directed therapies across gastrointestinal tract cancers \u2013 a new frontier","volume":"129","author":"Jones","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100382_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106053","article-title":"Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort","volume":"11","author":"Ter\u00e1n","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmogo.2026.100382_bib16","author":"Lee","year":"2025","journal-title":"Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100382_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108231","article-title":"Oncological outcomes of patients with oligometastatic oesophagogastric cancer","volume":"50","author":"Down","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1016\/j.esmogo.2026.100382_bib18","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4251\/wjgo.v11.i9.741","article-title":"Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: a systematic review","volume":"11","author":"Jamel","year":"2019","journal-title":"World J Gastrointest Oncol"},{"issue":"17_suppl","key":"10.1016\/j.esmogo.2026.100382_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4001","volume":"42","author":"Al-Batran","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmogo.2026.100382_bib20","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","article-title":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 Trial","volume":"3","author":"Al-Batran","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100382_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(23)00316-3","article-title":"Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial","volume":"9","author":"Liu","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.esmogo.2026.100382_bib22","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1007\/s11606-021-06737-1","article-title":"A consensus-based Checklist for Reporting of Survey Studies (CROSS)","volume":"36","author":"Sharma","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"13","key":"10.1016\/j.esmogo.2026.100382_bib23","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/0959-8049(95)00296-0","article-title":"The EORTC Core Quality of Life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy","volume":"31","author":"Kaasa","year":"1995","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100382_bib24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3961\/jpmph.24.272","article-title":"A comparison of green, delta, and Monte Carlo methods to select an optimal approach for calculating the 95% confidence interval of the population-attributable fraction: guidance for epidemiological research","volume":"57","author":"Lee","year":"2024","journal-title":"J Prev Med Public Health"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:37:15Z","timestamp":1792535835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819826000828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"alternative-id":["S2949819826000828"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100382","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinician and patient attitudes toward locoregional treatment of oligometastatic oesophago-gastric cancers: a mixed-methods study","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100382"}}